ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics

ERBB receptors were linked to human cancer pathogenesis approximately three decades ago. Biomedical investigators have since developed substantial understanding of the biology underlying the dependence of cancers on aberrant ERBB receptor signaling. An array of cancer-associated genetic alterations...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer cell Ročník 25; číslo 3; s. 282
Hlavní autoři: Arteaga, Carlos L, Engelman, Jeffrey A
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 17.03.2014
Témata:
Animals
Antibodies, Monoclonal, Humanized - therapeutic use
Drug Resistance, Neoplasm - genetics
ErbB Receptors - antagonists & inhibitors
ErbB Receptors - genetics
ErbB Receptors - metabolism
Humans
Mice
Neoplasms - drug therapy
Neoplasms - genetics
Neoplasms - metabolism
Receptor, ErbB-2 - antagonists & inhibitors
Receptor, ErbB-2 - genetics
Receptor, ErbB-2 - metabolism
Receptor, ErbB-3 - genetics
Receptor, ErbB-3 - metabolism
Receptor, ErbB-4
Signal Transduction
ISSN:1878-3686, 1878-3686
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:ERBB receptors were linked to human cancer pathogenesis approximately three decades ago. Biomedical investigators have since developed substantial understanding of the biology underlying the dependence of cancers on aberrant ERBB receptor signaling. An array of cancer-associated genetic alterations in ERBB receptors has also been identified. These findings have led to the discovery and development of mechanism-based therapies targeting ERBB receptors that have improved outcome for many cancer patients. In this Perspective, we discuss current paradigms of targeting ERBB receptors with cancer therapeutics and our understanding of mechanisms of action and resistance to these drugs. As current strategies still have limitations, we also discuss challenges and opportunities that lie ahead as basic scientists and clinical investigators work toward more breakthroughs.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1878-3686
1878-3686
DOI:10.1016/j.ccr.2014.02.025